Formula I Compounds Inhibiting BMI-1 Expression via RNA Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies lack effective agents that can inhibit BMI-1 expression, a critical component of polycomb repressive complex 1 involved in aberrant gene silencing and tumor suppression regulation, which is overexpressed in various cancers.
Innovation Solution
Development of specific compounds of formula I, which are designed to inhibit BMI-1 expression by modulating its protein levels and downstream targets, such as ubiquitinated histone H2A, and are administered as pharmaceutical compositions for treating or preventing cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer therapies are used, then treatment is provided, but effective inhibition of BMI-1 expression is not achieved
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to inhibit BMI-1 expression. These compounds bind to untranslated RNA of BMI-1, acting as a mediator between the therapeutic agent and the target protein, thereby achieving reliable inhibition of BMI-1 expression and its harmful effects in cancer cells
Solution Approach 2:
The invention changes the molecular parameters by developing compounds with specific chemical structures (formula I) that can selectively bind to BMI-1 untranslated RNA. This parameter change enables potent and specific inhibition of BMI-1 expression, overcoming the limitations of current therapies
2Reliability
If BMI-1 is targeted, then apoptosis and senescence occur in tumor cells, but effective agents for inhibiting BMI-1 expression are currently lacking
Solution Approach 1:
The patent creates synthetic copies of molecules that can bind to BMI-1 untranslated RNA, based on understanding of the RNA structure and binding requirements. These copied molecular structures (compounds of formula I) can be manufactured and provide reliable induction of apoptosis and senescence in tumor cells
Solution Approach 2:
The compounds induce apoptosis and senescence through self-service mechanisms by binding to BMI-1 untranslated RNA and blocking its function. This self-service approach eliminates the need for complex delivery systems or additional components, making the agents easier to manufacture while maintaining reliable tumor cell death
Data Source
AI summary
The invention provides a compound of formula I:or a salt thereof, wherein R2-R4 and p have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as anti-cancer agents.